OVARIAN TOXICITY OF FAC CHEMOTHERAPY IN RATS AND POSSIBILITY OF ITS CORRECTION WITH PLATELET-RICH PLASMA
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18393Keywords:
anti-Mullerian hormone, estradiol, FAC chemotherapy, follicle-stimulating hormone, ovarian toxicity, platelet-rich plasmaAbstract
Aim: To compare the dynamics of changes in the hormonal status of female rats in the setting of the FAC (5-fluorouracil, doxorubicin and cyclophosphamide) chemotherapy and after local administration of platelet-rich plasma (PRP). Materials and Methods: The study was carried out on female Wistar rats treated according to the FAC chemotherapy scheme (4 courses with a 3-week interval). The ovariotoxic effect of the FAC chemotherapy was assessed by the levels of anti-Mullerian hormone, estradiol (E2) and follicle-stimulating hormone in the proestrus phase. Three weeks after the last course of chemotherapy, 5 rats were administered with local intra- and periovarian injection of PRP (triply with a 1-week interval). Results: The dynamics of all investigated hormonal markers of the ovarian reserve in experimental animals was characterized by a progressive decrease in anti-Mullerian hormone and E2 levels and an increase in follicle-stimulating hormone level. The dynamics of the studied parameters after the serial administration of PRP demonstrated an improvement in the hormonal status. Conclusion: FAC chemotherapy in the experiment causes premature ovarian failure, and local administration of PRP improves the hormonal parameters of the ovarian reserve.
References
Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press) 2019; 11: 151–64. https://doi.org/10.2147/BCTT.S176070
DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017; 67: 439–48. https://doi.org/10.3322/caac.21412
Ghoncheh M, Mohammadian-Hafshejani A, Salehiniya H. Incidence and mortality of breast cancer and their relationship to development in Asia. Asian Pac J Cancer Prev 2015; 16: 6081–7. https://doi.org/10.7314/apjcp.2015.16.14.6081
Ghoncheh M, Momenimovahed Z, Salehiniya H. Epidemiology, incidence and mortality of breast cancer in Asia. Asian Pac J Cancer Prev 2016; 17: 47–52. https://doi.org/10.7314/apjcp.2016.17.s3.47
Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer 2005; 6: 391–401. https://doi.org/10.3816/cbc.2005.n.043
Tecza K, Pamula-Pilat J, Lanuszewska J, et al. Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. Oncotarget 2018; 9: 9114–36. https://doi.org/10.18632/oncotarget.24148
Montoya JE, Luna HG, Morelos AB, et al. Association of creatinine clearance with neutropenia in breast cancer patients undergoing chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (FAC). Med J Malaysia 2013; 68: 153–6.
Silva C, Caramelo O, Almeida-Santos T, et al. Factors associated with ovarian function recovery after chemotherapy for breast cancer: a systematic review and meta-analysis. Hum Reprod 2016; 31: 2737–49. https://doi.org/10.1093/humrep/dew224
Cathcart-Rake EJ, Ruddy KJ, Bleyer A, et al. Breast cancer in adolescent and young adult women under the age of 40 years. JCO Oncol Pract 2021; 17 : 305–13. https://doi.org/10.1200/OP.20.00793
Ra Hara G, Basu T. Platelet-rich plasma in regenerative medicine. BMRAT [Internet] 2014; 1: 25–31. https://doi.org/10.7603/s40730-014-0005-6
Graiet H, Lokchine A, Francois P, et al. Use of platelet-rich plasma in regenerative medicine: technical tools for correct quality control. BMJ Open Sport Exerc Med 2018; 4: 1111–5. https://doi.org/10.1136/bmjsem-2018-000442
Pavlovic V, Ciric M, Jovanovic V, et al. Platelet rich plasma: a short overview of certain bioactive components. Open Med (Wars) 2016; 11: 242–7. https://doi.org/10.1515/med-2016-0048
Everts P, Onishi K, Jayaram P, et al. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci 2020; 21: 7794. https://doi.org/10.3390/ijms21207794
Lichtarska AM, Sokol MM. The mechanism of action of platelet-rich plasma — composition analysis and safety assessment. Curr Issues Pharm Med Sci 2021; 34: 212–7. https://doi.org/10.2478/cipms-2021-0038
Fu XY, Chen HH, Zhang N, et al. Effects of chronic unpredictable mild stress on ovarian reserve in female rats: Feasibility analysis of a rat model of premature ovarian failure. Mol Med Rep 2018; 18: 532–40. https://doi.org/10.3892/mmr.2018.8989
Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 2016; 7: 27–31. https://doi.org/10.4103/0976-0105.177703
Ben-Aharon I, Shalgi R. What lies behind chemotherapy-induced ovarian toxicity? Reproduction 2012; 144: 153–63. https://doi.org/10.1530/REP-12-0121
Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol 2016; 12: 2333–44. https://doi.org/10.2217/fon-2016-0176
Naren G, Wang L, Zhang X, et al. The reversible reproductive toxicity of 5-fluorouracil in mice. Reprod Toxicol 2021; 101: 1–8. https://doi.org/10.1016/j.reprotox.2021.02.002
Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci 2021; 278: 119527. https://doi.org/10.1016/j.lfs.2021.119527
Aziz AUR, Yu X, Jiang Q, et al. Doxorubicin-induced toxicity to 3D-cultured rat ovarian follicles on a microfluidic chip. Toxicol In Vitro 2020; 62: 104677. https://doi.org/10.1016/j.tiv.2019.104677
Ben-Aharon I, Bar-Joseph H, Tzarfaty G, et al. Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol 2010; 8: 20. https://doi.org/10.1186/1477-7827-8-20
Xiao S, Zhang J, Liu M, et al. Doxorubicin has dose-dependent toxicity on mouse ovarian follicle development, hormone secretion, and oocyte maturation. Toxicol Sci 2017; 157: 320–9. https://doi.org/10.1093/toxsci/kfx047
Zhang T, He WH, Feng LL, et al. Effect of doxorubicin-induced ovarian toxicity on mouse ovarian granulosa cells. Regul Toxicol Pharmacol 2017; 86: 1–10. https://doi.org/10.1016/j.yrtph.2017.02.012
Voelcker G. The mechanism of action of cyclophosphamide and Its consequences for the development of a new generation of oxazaphosphorine cytostatics. Sci Pharm 2020; 88: 42. https://doi.org/10.3390/scipharm88040042
Marcozzi S, Rossi V, Salvatore G, et al. Distinct effects of epirubicin, cisplatin and cyclophosphamide on ovarian somatic cells of prepuberal ovaries. Aging (Albany NY) 2019; 11: 10532–56. https://doi.org/10.18632/aging.102476
Hao X, Anastácio A, Viñals-Ribé L, et al. Follicle rescue from prepubertal ovaries after recent treatment with cyclophosphamide-An experimental culture system using mice to achieve mature oocytes for fertility preservation. Front Oncol 2021; 11: 682470. https://doi.org/10.3389/fonc.2021.682470
Pascuali N, Scotti L, Di Pietro M, et al. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure. Hum Reprod 2018; 33: 844–59. https://doi.org/10.1093/humrep/dey045
Elkady MA, Shalaby S, Fathi F, et al. Effects of quercetin and rosuvastatin each alone or in combination on cyclophosphamide-induced premature ovarian failure in female albino mice. Hum Exp Toxicol 2019; 38: 1283–95. https://doi.org/10.1177/0960327119865588
Singh G, Misra R, Aggarwal A. Ovarian insufficiency is major short-term toxicity in systemic lupus erythematosus patients treated with cyclophosphamide. J Assoc Physicians India 2016; 64: 28–31.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
